Management of Pancreatectomy-Induced Diabetes (Type 3c)

Immediate Postoperative Insulin Protocol

• The American College of Surgeons recommends continuing IV insulin infusion targeting blood glucose 100-180 mg/dL until glucose stabilizes at ≤180 mg/dL for at least 24 hours AND oral feeding resumes 1, 2
• Monitor capillary blood glucose every 1-2 hours while NPO to detect dangerous glycemic excursions early 1, 2
• Do not transition to subcutaneous insulin if IV infusion rate exceeds 3 U/h, as this indicates severe insulin resistance and increased risk of postoperative complications 3

Critical Hypoglycemia Management

• Administer 15-20 grams IV dextrose immediately for any blood glucose <60 mg/dL, even without symptoms—these patients lack glucagon counter-regulation and cannot wait for symptomatic confirmation 1, 2
• Recheck glucose every 15 minutes after correction until glucose >100 mg/dL 1

Transition to Subcutaneous Insulin

• Administer subcutaneous long-acting insulin (glargine or detemir) 2 hours before discontinuing IV insulin to prevent dangerous rebound hyperglycemia 1, 2
• Calculate basal insulin dose as 50% of the total 24-hour IV insulin requirement when glucose was stable 1, 3, 4
• The remaining 50% becomes prandial insulin, divided by 3 meals using ultra-rapid insulin analogue (lispro, aspart, or glulisine) 1, 3, 4

Long-Term Insulin Management Strategy

• The basal-bolus scheme is mandatory for post-pancreatectomy patients as it significantly reduces postoperative complications compared to sliding-scale insulin alone (composite complications 8.6% vs 24.3%, OR 3.39, P=0.003) 1
• Basal insulin: Long-acting insulin (glargine or detemir) once daily, preferably at 20:00 hours 1, 3
• Prandial insulin: Ultra-rapid insulin analogue (lispro, aspart, or glulisine) before each meal, adjusted to carbohydrate intake 1, 3

Ongoing Monitoring Requirements

• Check capillary blood glucose before each meal and at bedtime once eating 1, 2
• Continue every 1-2 hours while NPO and receiving glucose-containing infusions 1
• Target glucose range in ICU setting: 140-180 mg/dL 1
• Target glucose range in ward setting: Individualized, but prioritize avoiding hypoglycemia over tight control 1

Management of Glycemic Emergencies

• For blood glucose >300 mg/dL, check for ketosis immediately in all patients 1, 2
• If ketonuria = 0 or ketonemia <0.5 mmol/L, administer 6 units ultra-rapid insulin subcutaneously and ensure adequate hydration 1
• Recheck glucose in 3 hours 1

Discharge Planning

• Continue the basal-bolus regimen established in hospital at discharge 1, 2
• Arrange endocrinology follow-up within 1 month for stable patients (HbA1c <8%) 1
• Request diabetologist consultation before discharge for HbA1c >9% or persistently unstable glucose levels >200 mg/dL 1

Insulin Glargine Transition Guidelines for Postoperative Surgical Patients

Prerequisites for Switching to Subcutaneous Glargine

• Adult postoperative surgical patients should have stable capillary glucose ≤180 mg/dL for at least 24 hours before conversion. 5
• Oral intake must have resumed prior to the transition. 5
• The continuous IV insulin infusion rate must be ≤3 U/hour; higher rates indicate severe insulin resistance and warrant continuation of IV therapy. 5

Calculation of the Basal (Glargine) Dose

• Determine the total 24‑hour IV insulin requirement by summing all units delivered during the most recent 24‑hour period when glucose was stable. 5
• Administer a single subcutaneous dose of insulin glargine equal to 50 % of that 24‑hour IV total. 5
• The remaining 50 % of the IV total is allocated to prandial (meal‑time) insulin, divided equally among three meals and delivered with an ultra‑rapid insulin analogue (e.g., lispro, aspart, or glulisine). 5

Timing of Glargine Administration

• Give the calculated glargine dose 2 hours before discontinuing the IV insulin infusion to avoid rebound hyperglycaemia or diabetic ketoacidosis. 5
• The preferred clock‑time for the glargine injection is 20:00 hours (8 PM). 5

Alternative Dosing for Insulin‑Naïve Patients

• In patients who have received IV insulin for less than 24 hours, are insulin‑naïve, and remain hyperglycaemic post‑operatively, start total daily insulin at 0.5–1 U/kg, split 50 % as basal glargine and 50 % as prandial rapid‑acting insulin. 5

Evidence Supporting the Basal‑Bolus Regimen

• The basal‑bolus approach more closely mimics normal pancreatic physiology by providing continuous basal insulin coverage plus meal‑related insulin spikes, which is associated with improved postoperative glycaemic control. 5

Strength of evidence: Not explicitly graded in the source; recommendations are based on observational data reported in the Anaesthesia journal. 5

Insulin Glargine Initiation and Transition Protocol for Post‑Operative NPO Patients Receiving Partial Parenteral Nutrition

Initial Dosing Strategy

• Initiate subcutaneous insulin glargine at 50 % of the total 24‑hour intravenous insulin requirement once the IV infusion rate has been stable at ≤ 3 U/hour for at least 24 hours, and give the dose 2 hours before discontinuing the IV insulin to avoid rebound hyperglycaemia or ketoacidosis. 6

Calculation of Basal Dose

• Determine the basal insulin dose by taking 50 % of the total 24‑hour IV insulin requirement recorded during the most recent period in which glucose has been ≤ 180 mg/dL for ≥ 24 hours. 6
• The remaining 50 % of the IV insulin total would normally be allocated to prandial insulin; however, in NPO patients receiving only partial parenteral nutrition, this prandial portion is initially withheld and replaced with correction‑dose insulin only. 6

Administration Timing

• Administer the calculated glargine dose subcutaneously 2 hours before stopping the IV insulin infusion to prevent rebound hyperglycaemia or diabetic ketoacidosis. 6
• For consistency, the preferred administration time is 20:00 hours (8 PM). 6

Dosing for Insulin‑Naïve Patients

• If the patient was insulin‑naïve pre‑operatively and IV insulin has been used for < 24 hours, start a total daily dose of 0.5–1.0 U/kg/day, allocating 50 % as basal glargine and holding the prandial component until oral intake resumes. 6
• For an average adult patient (~70 kg), this corresponds to a glargine dose of approximately 18–35 units once daily. 6

Transition Criteria (IV → Subcutaneous)

• Do not transition to subcutaneous insulin if the IV infusion rate exceeds 3 U/hour, as this indicates severe insulin resistance and higher risk of postoperative complications; continue IV insulin until the rate stabilises. 6

Transition to Full Basal‑Bolus Regimen

• Once oral intake resumes, convert to a full basal‑bolus regimen by adding rapid‑acting (ultra‑rapid) insulin before each meal. 6
• The prandial component should comprise the remaining 50 % of the original total daily dose, divided equally among three meals. 6
• Administer prandial insulin 0–15 minutes before meals to achieve optimal post‑prandial glucose control. 6

Safety Precautions

• Do not delay basal insulin administration; it must be given 2 hours before stopping IV insulin to prevent rebound hyperglycaemia. 6